Kevin D. Bowrin - Publications

Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.

Journal: Journal of medical economics

Published: August 23, 2022

Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England.

Journal: Vascular medicine (London, England)

Published: June 07, 2022

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.

Journal: Cardiovascular therapeutics

Published: February 25, 2022

Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands.

Journal: Journal of medical economics

Published: November 09, 2021

Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.

Journal: BMC medicine

Published: August 12, 2021

High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 04, 2021

Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes.

Journal: The American journal of managed care

Published: May 21, 2021

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.

Journal: Cardiovascular therapeutics

Published: May 19, 2021

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

Journal: PloS one

Published: November 19, 2020

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

Journal: Journal of market access & health policy

Published: September 18, 2020

Use of real-world evidence in meta-analyses and cost-effectiveness models.

Journal: Journal of medical economics

Published: July 14, 2020

Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease.

Journal: Angiology

Published: July 09, 2020